Moderna
MRNA
#1167
Rank
NZ$27.73 B
Marketcap
$72.07
Share price
-0.35%
Change (1 day)
-47.99%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.

Revenue for Moderna (MRNA)

Revenue in 2024 (TTM): NZ$8.01 Billion

According to Moderna 's latest financial reports the company's current revenue (TTM ) is NZ$8.74 Billion. In 2023 the company made a revenue of NZ$10.67 Billion a decrease over the revenue in the year 2022 that were of NZ$29.72 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Moderna from 2018 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) NZ$8.01 B-24.98%
2023 NZ$10.67 B-64.08%
2022 NZ$29.72 B14.49%
2021 NZ$25.96 B6728.48%
2020 NZ$0.38 B433.14%
2019 NZ$71.32 M-61.03%
2018 NZ$0.18 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$109.21 B 1,149.49%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.13 M-100.00%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$3.62 B-58.57%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$86.33 B 887.74%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NZ$6.13 M-99.93%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$151.60 B 1,634.49%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.33 B-96.19%๐Ÿ‡บ๐Ÿ‡ธ USA